vs
Alexander & Baldwin, Inc.（ALEX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Alexander & Baldwin, Inc.的季度营收约是REGENXBIO Inc.的1.7倍（$51.0M vs $30.3M），Alexander & Baldwin, Inc.净利率更高（7.4% vs -221.3%，领先228.7%），REGENXBIO Inc.同比增速更快（43.0% vs -18.4%），Alexander & Baldwin, Inc.自由现金流更多（$27.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -8.7%）
亚历山大-鲍德温公司是一家美国企业，曾是夏威夷领地时期五大财团之一，也是五大财团中最晚停止甘蔗种植的企业。目前公司主营房地产开发、土地运营以及建材与建筑业务，截至2020年，该公司是夏威夷最大的私人土地持有者之一，在当地拥有超2.8万英亩土地，运营着36处收益性物业。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ALEX vs RGNX — 直观对比
营收规模更大
ALEX
是对方的1.7倍
$30.3M
营收增速更快
RGNX
高出61.4%
-18.4%
净利率更高
ALEX
高出228.7%
-221.3%
自由现金流更多
ALEX
多$80.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-8.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $51.0M | $30.3M |
| 净利润 | $3.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 17.1% | -190.0% |
| 净利率 | 7.4% | -221.3% |
| 营收同比 | -18.4% | 43.0% |
| 净利润同比 | -69.7% | -31.2% |
| 每股收益（稀释后） | $0.05 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALEXRGNX
| Q4 25 | $51.0M | $30.3M | ||
| Q3 25 | $50.2M | $29.7M | ||
| Q2 25 | $51.7M | $21.4M | ||
| Q1 25 | $53.7M | $89.0M | ||
| Q4 24 | $62.4M | $21.2M | ||
| Q3 24 | $61.9M | $24.2M | ||
| Q2 24 | $51.0M | $22.3M | ||
| Q1 24 | $61.2M | $15.6M |
净利润ALEXRGNX
| Q4 25 | $3.8M | $-67.1M | ||
| Q3 25 | $14.3M | $-61.9M | ||
| Q2 25 | $25.1M | $-70.9M | ||
| Q1 25 | $21.4M | $6.1M | ||
| Q4 24 | $12.4M | $-51.2M | ||
| Q3 24 | $19.0M | $-59.6M | ||
| Q2 24 | $9.1M | $-53.0M | ||
| Q1 24 | $20.0M | $-63.3M |
毛利率ALEXRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ALEXRGNX
| Q4 25 | 17.1% | -190.0% | ||
| Q3 25 | 38.2% | -176.3% | ||
| Q2 25 | 54.4% | -296.3% | ||
| Q1 25 | 44.6% | 13.6% | ||
| Q4 24 | 28.3% | -242.1% | ||
| Q3 24 | 35.6% | -256.6% | ||
| Q2 24 | 31.8% | -251.3% | ||
| Q1 24 | 38.9% | -408.8% |
净利率ALEXRGNX
| Q4 25 | 7.4% | -221.3% | ||
| Q3 25 | 28.5% | -208.3% | ||
| Q2 25 | 48.6% | -331.8% | ||
| Q1 25 | 39.9% | 6.8% | ||
| Q4 24 | 19.9% | -241.3% | ||
| Q3 24 | 30.7% | -246.3% | ||
| Q2 24 | 17.8% | -237.7% | ||
| Q1 24 | 32.6% | -405.4% |
每股收益（稀释后）ALEXRGNX
| Q4 25 | $0.05 | $-1.30 | ||
| Q3 25 | $0.20 | $-1.20 | ||
| Q2 25 | $0.35 | $-1.38 | ||
| Q1 25 | $0.29 | $0.12 | ||
| Q4 24 | $0.16 | $-0.99 | ||
| Q3 24 | $0.26 | $-1.17 | ||
| Q2 24 | $0.13 | $-1.05 | ||
| Q1 24 | $0.28 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.3M | $230.1M |
| 总债务越低越好 | $491.6M | — |
| 股东权益账面价值 | $987.2M | $102.7M |
| 总资产 | $1.7B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.50× | — |
8季度趋势，按日历期对齐
现金及短期投资ALEXRGNX
| Q4 25 | $11.3M | $230.1M | ||
| Q3 25 | $17.3M | $274.2M | ||
| Q2 25 | $8.6M | $323.3M | ||
| Q1 25 | $16.9M | $267.9M | ||
| Q4 24 | $33.4M | $234.7M | ||
| Q3 24 | $17.9M | $255.5M | ||
| Q2 24 | $29.5M | $290.4M | ||
| Q1 24 | $15.7M | $338.7M |
总债务ALEXRGNX
| Q4 25 | $491.6M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $474.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALEXRGNX
| Q4 25 | $987.2M | $102.7M | ||
| Q3 25 | $1.0B | $161.5M | ||
| Q2 25 | $1.0B | $213.7M | ||
| Q1 25 | $1.0B | $274.2M | ||
| Q4 24 | $1.0B | $259.7M | ||
| Q3 24 | $998.2M | $301.4M | ||
| Q2 24 | $1.0B | $348.3M | ||
| Q1 24 | $1.0B | $390.7M |
总资产ALEXRGNX
| Q4 25 | $1.7B | $453.0M | ||
| Q3 25 | $1.7B | $525.2M | ||
| Q2 25 | $1.6B | $581.0M | ||
| Q1 25 | $1.6B | $490.9M | ||
| Q4 24 | $1.7B | $466.0M | ||
| Q3 24 | $1.7B | $519.1M | ||
| Q2 24 | $1.6B | $569.4M | ||
| Q1 24 | $1.6B | $629.2M |
负债/权益比ALEXRGNX
| Q4 25 | 0.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $79.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $27.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 53.5% | -174.0% |
| 资本支出强度资本支出/营收 | 102.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 21.06× | — |
| 过去12个月自由现金流最近4个季度 | $57.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ALEXRGNX
| Q4 25 | $79.5M | $-52.3M | ||
| Q3 25 | $24.5M | $-56.0M | ||
| Q2 25 | $16.5M | $-49.3M | ||
| Q1 25 | $26.0M | $33.6M | ||
| Q4 24 | $98.0M | $-31.6M | ||
| Q3 24 | $35.3M | $-40.5M | ||
| Q2 24 | $22.3M | $-45.5M | ||
| Q1 24 | $16.1M | $-55.5M |
自由现金流ALEXRGNX
| Q4 25 | $27.3M | $-52.8M | ||
| Q3 25 | $-3.7M | $-56.5M | ||
| Q2 25 | $11.8M | $-49.7M | ||
| Q1 25 | $21.8M | $32.6M | ||
| Q4 24 | $77.0M | $-32.7M | ||
| Q3 24 | $31.4M | $-40.9M | ||
| Q2 24 | $18.0M | $-46.0M | ||
| Q1 24 | $12.3M | $-56.0M |
自由现金流率ALEXRGNX
| Q4 25 | 53.5% | -174.0% | ||
| Q3 25 | -7.4% | -189.9% | ||
| Q2 25 | 22.8% | -232.8% | ||
| Q1 25 | 40.6% | 36.6% | ||
| Q4 24 | 123.4% | -154.2% | ||
| Q3 24 | 50.8% | -168.9% | ||
| Q2 24 | 35.3% | -206.2% | ||
| Q1 24 | 20.1% | -358.5% |
资本支出强度ALEXRGNX
| Q4 25 | 102.4% | 1.7% | ||
| Q3 25 | 56.1% | 1.7% | ||
| Q2 25 | 9.1% | 1.8% | ||
| Q1 25 | 7.8% | 1.2% | ||
| Q4 24 | 33.5% | 5.1% | ||
| Q3 24 | 6.2% | 1.3% | ||
| Q2 24 | 8.4% | 2.1% | ||
| Q1 24 | 6.1% | 3.6% |
现金转化率ALEXRGNX
| Q4 25 | 21.06× | — | ||
| Q3 25 | 1.71× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 1.21× | 5.53× | ||
| Q4 24 | 7.88× | — | ||
| Q3 24 | 1.86× | — | ||
| Q2 24 | 2.45× | — | ||
| Q1 24 | 0.80× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALEX
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
